Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other Working Capital Changes: 2015-2024

Historic Other Working Capital Changes for UroGen Pharma (URGN) over the last 10 years, with Dec 2024 value amounting to -$1.4 million.

  • UroGen Pharma's Other Working Capital Changes fell 96.37% to $67,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 million, marking a year-over-year increase of 2.72%. This contributed to the annual value of -$1.4 million for FY2024, which is 75.12% down from last year.
  • Per UroGen Pharma's latest filing, its Other Working Capital Changes stood at -$1.4 million for FY2024, which was down 75.12% from -$820,000 recorded in FY2023.
  • UroGen Pharma's Other Working Capital Changes' 5-year high stood at $4.1 million during FY2021, with a 5-year trough of -$1.4 million in FY2024.
  • Its 3-year average for Other Working Capital Changes is $456,667, with a median of -$820,000 in 2023.
  • In the last 5 years, UroGen Pharma's Other Working Capital Changes skyrocketed by 491.37% in 2020 and then slumped by 122.61% in 2023.
  • UroGen Pharma's Other Working Capital Changes (Yearly) stood at $2.3 million in 2020, then soared by 76.44% to $4.1 million in 2021, then fell by 11.80% to $3.6 million in 2022, then tumbled by 122.61% to -$820,000 in 2023, then plummeted by 75.12% to -$1.4 million in 2024.